Septerna, Inc. Common Stock (SEPN) - Total Liabilities
Based on the latest financial reports, Septerna, Inc. Common Stock (SEPN) has total liabilities worth $217.92 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Septerna, Inc. Common Stock - Total Liabilities Trend (2022–2024)
This chart illustrates how Septerna, Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data. See Septerna, Inc. Common Stock working capital to net assets to evaluate short-term liquidity relative to the company's equity base.
Septerna, Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of Septerna, Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Edelweiss Financial Services Limited
NSE:EDELWEISS
|
India | Rs365.40 Billion |
|
GuoChuang Software Co Ltd
SHE:300520
|
China | CN¥1.84 Billion |
|
Huafon Microfibre Shanghai Co
SHE:300180
|
China | CN¥1.56 Billion |
|
First Tractor Co Ltd
SHG:601038
|
China | CN¥6.66 Billion |
|
Xinjiang Tecon Animal Husbandry Bio-Technology Co Ltd
SHE:002100
|
China | CN¥9.60 Billion |
|
Tessenderlo
BR:TESB
|
Belgium | €938.20 Million |
|
Luolai Home Textile Co Ltd
SHE:002293
|
China | CN¥2.53 Billion |
|
Blackbaud Inc
NASDAQ:BLKB
|
USA | $2.31 Billion |
Liability Composition Analysis (2022–2024)
This chart breaks down Septerna, Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market value of Septerna, Inc. Common Stock.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.53 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.56 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.36 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Septerna, Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Septerna, Inc. Common Stock (2022–2024)
The table below shows the annual total liabilities of Septerna, Inc. Common Stock from 2022 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $36.51 Million | -78.43% |
| 2023-12-31 | $169.24 Million | +110.71% |
| 2022-12-31 | $80.32 Million | -- |
About Septerna, Inc. Common Stock
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 … Read more